Key result
HF quadrotherapy improves LVEF and cardiac status in two cancer patients, enabling successful antitumor treatment.
Why the study?
Chronic heart failure complicates cancer treatment, and key drug classes including mineralocorticoid receptor inhibitors, ARNIs, and SGLT2 inhibitors have not been studied in cancer patients.
Does quadruple therapy improve cardiac function in patients with severe chronic heart failure and active cancer?
Case Report (n=2)
Does quadruple therapy improve cardiac function in patients with severe chronic heart failure and active cancer?
Quadruple therapy for heart failure can improve cardiac function in patients with severe CHF and active cancer, enabling them to undergo necessary oncological treatments.
May inform individualized CHF management during cancer therapy; leaves open efficacy of ARNI, MRA, and SGLT2i in oncology populations.
Background: Chronic heart failure (CHF) for a patient with cancer is complex, as it complicates antitumor treatment. In some cases, severe CHF is a contraindication to the chemotherapy or surgical treatment. Despite significant progress in CHF treatment, some groups of drugs, particularly mineralocorticoid receptor inhibitors, angiotensin receptor-neprilysin inhibitors, and sodium-glucose co-transporter type 2 inhibitors, have not been studied related to cancer patients. Clinical case description: In this report, we introduce two clinical cases in which, because of the invaluable contribution of the cardio-oncological team, we have managed to solve complex problems of treating patients with CHF and cancer. In patient 1 with severe CHF, it was possible to achieve regression of systolic dysfunction, despite the progression of bladder cancer T4N1M0. In patient 2 with severe ischemic cardiopathy and CHF, owing to the timely administration of quadruple therapy, we managed to significantly improve the cardiac status and increase the LV EF that the patient underwent gastrectomy and cholecystectomy for cancer of the cardiac part of the stomach cT2N0M0 without complications. Conclusion: The above clinical cases demonstrate the possibilities of a team, multidisciplinary approach in the treatment of complex category of patients with CHF and active oncological disease. Modern therapy of cancer patients with severe heart failure allows successful antitumor treatment.
No takes yet. Share an insight, caveat, or question.
Peresada et al. (2023) conducted a case report in Chronic heart failure and cancer (n=2). Quadrotherapy (ARNI, beta-blocker, MRA, and SGLT2 inhibitor) was evaluated on Improvement in cardiac status and left ventricular ejection fraction. Quadrotherapy for chronic heart failure, including SGLT2 inhibitors, improved left ventricular ejection fraction and cardiac status in two cancer patients, enabling successful antitumor treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: